Skip to main content

Advertisement

Table 1 Patients’ characteristics and factors affecting CR in 102 evaluable treated AML patients

From: Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia

Factors Number of patients Complete remission N (%) p
Age (years)
 < 60 79 61 (77) 0.019
 ≥ 60 23 12 (52)
White blood cell count
 < 100,000/μL 20 14 (70) 0.862
 > 100,000/μL 82 59 (72)
Cytogenetic risk
 Favorable 7 6 (86) 0.051
 Intermediate 71 54 (76)
 Adverse 24 13 (54)
Gene mutation
 FLT3-ITD 8 5 (63) 0.453
 NPM1 13 11 (85)
 FLT3-ITD and NPM1 6 5 (83)
 CEBPA 10 7 (70)
 No mutation 64 46 (72)
 Co-existence of mutant CEBPA with other gene mutation 1 1 (100)
Single FLT3-ITD mutation
 Yes 8 5 (63) 0.554
 No 94 68 (72)
Single NPM1 mutation
 Yes 13 11 (85) 0.100
 No 89 62 (70)
Single CEBPA mutation
 Yes 10 7 (70) 0.198
 No 92 65 (71)
Induction chemotherapy
 7 + 3 80 61 (76) 0.000
 5 + 2 16 12 (75)
 Azacitidine 6 0